Rifaximin
Treatment for Irritable Bowel Syndrome
Typical Dosage: 550 mg orally three times daily for 14 days
Effectiveness
65%
Safety Score
70%
Clinical Trials
24
Participants
9K
Comparative Safety Scale(Higher is safer)
Cyanideā ļø
Methš
Cigarettesš¬
Chemoā¢ļø
Alcoholšŗ
Morphineš
Antibioticsš
Tylenolš
Exerciseš
Waterš§
70
DangerousModerateSafe
Treatment Details
Dosage Range
550 mg orally three times daily for 14 days
Time to Effect
1-2 weeks
Treatment Duration
14-day course, potentially repeated for recurrence
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
100(Treat 100 patients to see 1 additional serious adverse event)
Confidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$18,000
Monitoring:$200
Side Effect Mgmt:$150
Total Annual:$18,350
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$120,000/QALY
QALYs Gained
0.07
Outcome-Based Costs
Cost per Responder
$61,167
Cost per Remission
$183,500
Comparison vs Loperamide
Cost Difference
+$17,800/year
More expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
No dominance
Prescription Access Economics
Annual Societal Loss per Patient
$14,510
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$250/year
Time Cost
$120/year
Travel + wait time
Insurance Admin Cost
$40/year
Prior auth, claims
Rx Price
$18,000/year
Potential OTC Price
$3,600/year
Estimated if OTC available
Early Treatment Benefit
+0.05 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
MODERATERifaximin Outcomes
for Irritable Bowel Syndrome
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+30%
Remission Rate
+10%
Common Side Effects
Nausea
+14%
Abdominal pain
+7%
Diarrhea
+5%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
1 active trial recruiting for Rifaximin in Irritable Bowel Syndrome
Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders
NCT07522255NOT YET RECRUITINGPHASE3
78 participants
INTERVENTIONAL
Bangkok Noi, Thailand
Started: Apr 1, 2026
Completed Clinical Trials
13 completed trials for Rifaximin in Irritable Bowel Syndrome
Rifaximin for the Treatment of Irritable Bowel Syndrome
NCT00259155COMPLETEDPHASE2
92 participants
INTERVENTIONAL
Started: Jul 1, 2003
Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome
NCT00269412COMPLETEDPHASE2
525 participants
INTERVENTIONAL
Scottsdale, United States +66 more
Started: Dec 1, 2005
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
NCT01543178COMPLETEDPHASE3
2.58K participants
INTERVENTIONAL
Anniston, United States +295 more
Started: Feb 1, 2012
Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea
NCT03729271COMPLETEDPHASE4
148 participants
INTERVENTIONAL
Ann Arbor, United States
Started: Jan 9, 2020
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
NCT00731679COMPLETEDPHASE3
623 participants
INTERVENTIONAL
Hueytown, United States +95 more
Started: Jul 1, 2008
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
NCT00724126COMPLETEDPHASE3
637 participants
INTERVENTIONAL
Anniston, United States +87 more
Started: Jul 1, 2008
A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing
NCT03219528COMPLETEDPHASE4
74 participants
INTERVENTIONAL
Ann Arbor, United States
Started: Feb 13, 2018
Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome
NCT03557788COMPLETEDPHASE4
33 participants
INTERVENTIONAL
Singapore, Singapore
Started: May 7, 2018
The Efficacy of Probiotics as an Adjunct to Treatment of SIBO With Rifaximin
NCT06223685COMPLETEDNA
129 participants
INTERVENTIONAL
Szczecin, Poland
Started: Apr 1, 2023
Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome
NCT00945334COMPLETEDNA
37 participants
INTERVENTIONAL
Los Angeles, United States +1 more
Started: Aug 1, 2009
Efficacy and Safety of Rifaximin With NAC in IBS-D
NCT04557215COMPLETEDPHASE1, PHASE2
45 participants
INTERVENTIONAL
Los Angeles, United States
Started: Nov 13, 2020
To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea
NCT05867550COMPLETEDPHASE4
162 participants
INTERVENTIONAL
Karachi, Pakistan
Started: Jan 3, 2023
Gulf War Digestive Health Study
NCT00680836COMPLETEDNA
54 participants
INTERVENTIONAL
Salt Lake City, United States
Started: Oct 1, 2007
Showing 20 of 25 total trials